Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDAPRNewsWire • 10/01/23
Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight LossSeeking Alpha • 09/29/23
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g.PRNewsWire • 09/27/23
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 StocksThe Motley Fool • 09/14/23
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of SchedulePRNewsWire • 09/06/23
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIVPRNewsWire • 09/05/23
CVS Health Just Created a New Problem For Viatris. Here's What You Need to KnowThe Motley Fool • 09/01/23
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 08/30/23
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 08/23/23